Compound · ipamorelin
T2Peptide

Ipamorelin

Selective ghrelin receptor (GHS-R1a) agonist. Stimulates pituitary GH release without significantly elevating cortisol, prolactin, or ACTH — unique selectivity among growth hormone secretagogues. Does not produce appetite stimulation at standard doses. Synergistic with GHRH analogs.

Half-life
2 hours
Bioavailability
Systemic via subcutaneous injection
Route
subcutaneous
Evidence tier
T2 — Single-RCT or mechanistic
Optimization pillars
anti-aging · recovery
References
2 peer-reviewed
Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative
100–200 mcg/injection 1-2x/day
GH support
moderate
200–300 mcg/injection 2-3x/day
Anti-aging
aggressive
300 mcg/injection 3x/day
Maximum GH pulse
Monitoring
  • igf-1
  • fasting-glucose
  • cortisol
Contraindications
  • active-cancer
  • pituitary-tumor
References
  • PMID:9849822Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol, 1998
  • PMID:10372583Safety and tolerability of ipamorelin in healthy volunteersGrowth Horm IGF Res, 1999
Notes

Ipamorelin is the cleanest GH secretagogue. No cortisol spike. No prolactin elevation. No appetite surge. That selectivity profile is why it became the default pairing with Mod GRF 1-29. The two peptides hit different receptors on the same cell — GHRH receptor and ghrelin receptor — producing additive GH output without additive side effects. If you are building a GH peptide stack, this is the foundation compound.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Ipamorelin in a protocol matched to you

OPTIMIZE · a protocols.is product